Research Progress of Artemisinin and Its Derivatives Based on Ferroptosis in Lymphatic System Malignancies--Review.
10.19746/j.cnki.issn.1009-2137.2025.04.047
- Author:
Yu-Xin WEI
1
;
Yi-Fan YANG
1
;
Jiong-Ping HAN
1
;
Wei-Ying FENG
1
Author Information
1. Department of Hematology， Shaoxing People's Hospital (The First Affiliated Hospital, Shaoxing University)， Shaoxing 312000， Zhejiang Province， China.
- Publication Type:English Abstract
- Keywords:
ferroptosis； dihydroartemisinin； artesunate； lymphoid malignancies
- MeSH:
Humans;
Ferroptosis/drug effects*;
Artemisinins/therapeutic use*;
Signal Transduction
- From:
Journal of Experimental Hematology
2025;33(4):1237-1240
- CountryChina
- Language:Chinese
-
Abstract:
Ferroptosis, an iron-dependent form of regulated cell death, is mechanistically characterized by disrupted iron homeostasis, lipid peroxidation, and compromised antioxidant defense systems. Recent studies have demonstrated that artemisinin and its derivatives, such as dihydroartemisinin and artesunate, exhibit therapeutic potential against lymphatic system malignancies through ferroptosis induction. These compounds exert their antitumor effects by modulating critical regulatory proteins including SLC7A11, GPX4, and STAT3, as well as activating pivotal signaling pathways such as ATF4-CHOP and SREBP2-IPP-GPX4 axes. Notably, synergistic therapeutic effects have been observed when artemisinin derivatives are combined with conventional chemotherapeutic agents or targeted therapies, demonstrating enhanced tumor-suppressive activity and circumvention of drug resistance mechanisms. This review systematically summarizes recent advancements in understanding the ferroptosis-mediated antitumor mechanisms of artemisinin compounds in lymphoid malignancies, with particular emphasis on their molecular targets and clinical translational potential.
